Tivic Health Systems (TIVC) Set to Announce Quarterly Earnings on Tuesday

Tivic Health Systems (NASDAQ:TIVC) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 14th. Analysts expect the company to announce earnings of ($7.00) per share for the quarter.

Tivic Health Systems (NASDAQ:TIVC) last released its quarterly earnings results on Monday, August 14th. The company reported ($7.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.00) by $1.00. Tivic Health Systems had a negative net margin of 638.47% and a negative return on equity of 204.39%. The company had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.63 million. On average, analysts expect Tivic Health Systems to post $-33 EPS for the current fiscal year and $-24 EPS for the next fiscal year.

Tivic Health Systems Stock Up 0.8 %

Shares of NASDAQ:TIVC opened at $1.19 on Friday. Tivic Health Systems has a twelve month low of $1.15 and a twelve month high of $174.00. The company has a market cap of $1.75 million, a price-to-earnings ratio of -0.02 and a beta of 2.08. The business has a 50 day moving average price of $1.78 and a 200 day moving average price of $6.40.

Institutional Investors Weigh In On Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Renaissance Technologies LLC purchased a new stake in Tivic Health Systems, Inc. (NASDAQ:TIVC) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 122,234 shares of the company’s stock, valued at approximately $197,000. Renaissance Technologies LLC owned 1.27% of Tivic Health Systems at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.62% of the company’s stock.

Tivic Health Systems Company Profile

Tivic Health Systems Inc operates as a health technology company, focuses on developing and commercializing non-invasive bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal congestion pains. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.